Evidence map›Paper›PMID 41020222›Full record

ArticleFrontiers in medicine2025

High rate of seroeligibility among

Milind Y Desai, Daniele Massera, Heng Wang, Timothy C Wong, Omar Wever-Pinzon, Neal K Lakdawala, John R Giudicessi, Theodore Abraham, Sherif Nagueh, Florian Rader and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Milind Y DesaiCleveland Clinic Foundation, Cleveland, OH, United States.
Daniele MasseraNYU Langone, New York, NY, United States.
Heng WangDDC Clinic for Special Needs Children, Middlefield, OH, United States.
Timothy C WongUPMC Hypertrophic Cardiomyopathy Center, University of Pittsburgh, Pittsburgh, PA, United States.
Omar Wever-PinzonAdvanced Heart Failure Treatment and Recovery Section, University of Utah Health Sciences Center, Salt Lake City, UT, United States.
Neal K LakdawalaBrigham and Women's Hospital, Boston, MA, United States.
John R GiudicessiMayo Clinic, Rochester, MN, United States.
Theodore AbrahamUCSF HCM Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
Sherif NaguehHouston Methodist, Houston, TX, United States.
Florian RaderCedars-Sinai Medical Center, West Hollywood, CA, United States.
Ahmad MasriOregon Health and Science University School of Medicine, Portland, OR, United States.
Emre TurerThe University of Texas Southwestern Medical Center, Dallas, TX, United States.
Pfumo MushongaBioagilatyx, NC, United States.
Elizabeth Butala FloresBioagilatyx, NC, United States.
William HarrisonTenaya Therapeutics, South San Francisco, CA, United States.
Natalia Sonicheva-PatersonTenaya Therapeutics, South San Francisco, CA, United States.
Gretchen ArgastTenaya Therapeutics, South San Francisco, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The genetic etiology of hypertrophic cardiomyopathy (HCM) and the critical role of sarcomeric variants in its pathogenesis are well recognized (1). Among these, loss-of-function variants in the myosin binding protein C gene ( Methods: This was a prospective, cross-sectional study of 100 adults (aged 18-65 years) with symptomatic Results: Pre-existing anti-AAV9 NAb were undetectable in 50% of patients. Among those with detectable titers (range: 1:10-1:720), only 16% exceeded 1:40. TAb were undetectable in 53%; titers ranged from 1:10 to 1:65,600. A strong correlation was observed between NAb and TAb titers (r = 0.671, Conclusion: Pre-existing immunity to AAV9 was absent or low in most

Indexed as

adenoassociated virus 9gene therapyHCMMYBPC3seroprevalence

Identifiers

PMID41020222
PMCPMC12463840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.